Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Trial details
- Registry ID
- NCT05415137
- Drugs studied
- Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg
TrialRedline tracks 3 clinical trials sponsored by aTyr Pharma, Inc.: 1 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisNCT05415137 | Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg | Completed | 2025-06-25Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)NCT05892614 | efzofitimod 270 mg, efzofitimod 450 mg | Recruiting | 2026-04Estimated |
| Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19NCT04412668 | Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg | Completed | 2020-10-23Actual |
Names as written in the registry records.
NCT05415137 · aTyr Pharma, Inc.
Before: Estimated. After: Actual.
Before: 31 Jul 2025. After: 25 Jun 2025.
Before: Active not recruiting. After: Completed.